PGR and metastatic neoplasm: GATA3 mutations were observed in a statistically significant larger percentage of patients with documented visceral disease (76.8% vs. 62.0%; p = 0.016) and de novo metastatic disease (33.3% vs. 20.7%; p = 0.018) compared to GATA3WT; no other distinguishing clinical characteristics, including age at metastatic diagnosis, number of prior therapies, and progesterone receptor status, were observed (see Table 1 for clinical characteristics & mutational status of the cohort).